TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21667134

Group type: EXPERIMENTAL
Intervention: Preoperative S-1 (80 mg/m²/day, days 1-21) plus cisplatin (60 mg/m² on day 8) for 2 courses followed by radical gastrectomy and postoperative S-1 (80 mg/m²/day, days 1-14) every 3 weeks for 1 year
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: R0 resection
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Patients with Cy1 alone
Number of subjects: 51
Study: 21668743

Group type: EXPERIMENTAL
Intervention: Catastrophizing
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: State anxiety
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Anger
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Trait anxiety
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Intensity of LBP
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Failed back surgery
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Higher academic level
Number of subjects: 123
Study: 21668817

Group type: EXPERIMENTAL
Intervention: Positive cat allergen-induced BHR (≥ 20% histamine release)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Positive cat allergen-induced BHR
Number of subjects: 42

Group type: COMPARATOR
Intervention: Negative cat allergen-induced BHR
Number of subjects: 42
Study: 21668924

Group type: EXPERIMENTAL
Intervention: Dipeptidyl peptidase-4 inhibitor sitagliptin
Number of subjects: 0
Study: 21669404

Group type: EXPERIMENTAL
Intervention: AMD patients
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 21670382

Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment
Number of subjects: 4731
Study: 21670448

Group type: EXPERIMENTAL
Intervention: DNMT3A mutations
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: DNMT3A mutations in cytogenetically normal (CN) AML
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: NPM1/FLT3-ITD high-risk patients with DNMT3A mutations
Number of subjects: 489
Study: 21670449

Group type: EXPERIMENTAL
Intervention: Imatinib 260 mg/m² daily
Number of subjects: 44
Study: 21673350

Group type: EXPERIMENTAL
Intervention: Epratuzumab (E) 360 mg/m² intravenously with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) for 6 cycles
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Epratuzumab with R-CHOP (ER-CHOP)
Number of subjects: 107

Group type: COMPARATOR
Intervention: R-CHOP (control group)
Number of subjects: 107
Study: 21674002

Group type: EXPERIMENTAL
Intervention: n-3 PUFA levels below the population median, GCKR C/C genotype
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: n-3 PUFA levels above the median, GCKR C/C genotype
Number of subjects: 379
Study: 21674178

Group type: EXPERIMENTAL
Intervention: Hyperglycaemia (18 mmol/l)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypoglycaemia (2.5 mmol/l) followed by hyperglycaemia (12 mmol/l) and another hypoglycaemia (3.0 mmol/l)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeated hypoglycaemia
Number of subjects: 0
Study: 21675055

Group type: EXPERIMENTAL
Intervention: Erythropoietin (exact dosage and duration not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Erythropoietin (in the context of EPO-TBI trial)
Number of subjects: 0
Study: 21676042

Group type: EXPERIMENTAL
Intervention: Asthma group (asthma diagnosis)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Inflammatory group (no asthma diagnosis, elevated FE(NO) and/or BHR)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Non-inflammatory group (no asthma diagnosis, no BHR, normal FE(NO))
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: BHR (Bronchial Hyperreactivity)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Eosinophil count
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Total IgE
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Nasal outcomes
Number of subjects: 57
Study: 21676121

Group type: EXPERIMENTAL
Intervention: PDE5i
Number of subjects: 24708
Study: 21676217

Group type: EXPERIMENTAL
Intervention: Lapatinib 1250 mg/day continuously and capecitabine 1000 mg/m2 twice daily on a 2-week-on and 1-week-off schedule
Number of subjects: 67

Group type: COMPARATOR
Intervention: Trastuzumab-containing regimen
Number of subjects: 67
Study: 21676222

Group type: EXPERIMENTAL
Intervention: Case management group
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 112
Study: 21676394

Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol (35 μg) and norgestimate (0.18/0.215/0.25 mg) for 6 cycles
Number of subjects: 29
Study: 21676694

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavior therapy (CBT)
Number of subjects: 80
Study: 21677057

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass surgery
Number of subjects: 65
Study: 21677060

Group type: EXPERIMENTAL
Intervention: Posting point-of-purchase nutrition information in university canteens
Number of subjects: 224
Study: 21679735

Group type: EXPERIMENTAL
Intervention: Autologous heat inactivated HIV-1 virions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Autologous dendritic-cell-based therapeutic HIV-1 vaccine
Number of subjects: 0
Study: 21680644

Group type: EXPERIMENTAL
Intervention: REVEAL Registry predictive algorithm
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Simplified risk score calculator
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Full predictive algorithm
Number of subjects: 504
Study: 21680850

Group type: EXPERIMENTAL
Intervention: Aliskiren (oral direct renin inhibitor) for 12 months
Number of subjects: 25
Study: 21680946

Group type: EXPERIMENTAL
Intervention: 99mTc-DI-80B3/SPECT
Number of subjects: 52

Group type: COMPARATOR
Intervention: Contrast-enhanced multidetector thoracic CT scan
Number of subjects: 52
Study: 21681115

Group type: EXPERIMENTAL
Intervention: Sparse stool sampling for percentage fat (PF) analysis
Number of subjects: 12

Group type: COMPARATOR
Intervention: 72-hour coefficient of fat absorption (CFA) measurement
Number of subjects: 12
Study: 21684515

Group type: EXPERIMENTAL
Intervention: Peisner Platform
Number of subjects: 10
Study: 21684668

Group type: EXPERIMENTAL
Intervention: Tracheal rapid ultrasound exam (T.R.U.E.)
Number of subjects: 112
Study: 21685174

Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg loading dose
Number of subjects: 760
Study: 21685468

Group type: EXPERIMENTAL
Intervention: (18)Fluoro-deoxy-Glucose Positron Emission Tomography/Computed Tomography (FDG-PET/CT)
Number of subjects: 10
Study: 21685540

Group type: EXPERIMENTAL
Intervention: 800 mg EFV with RFN
Number of subjects: 72

Group type: COMPARATOR
Intervention: 600 mg EFV with RFN
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 72
Study: 21686825

Group type: EXPERIMENTAL
Intervention: Orthopaedic full spinal supports along with conventional treatment
Number of subjects: 4

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 4
Study: 21689411

Group type: EXPERIMENTAL
Intervention: Donepezil 23 mg/day
Number of subjects: 1467

Group type: COMPARATOR
Intervention: Donepezil 10 mg/day
Number of subjects: 1467
Study: 21689421

Group type: EXPERIMENTAL
Intervention: Higher protein diet with glucosamine, chondroitin, and MSM supplementation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Higher carbohydrate diet with glucosamine, chondroitin, and MSM supplementation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Higher protein diet without supplementation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Higher carbohydrate diet without supplementation
Number of subjects: 30
Study: 21690488

Group type: EXPERIMENTAL
Intervention: hcmv-miR-UL112, miR-296-5p, let-7e
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: HCMV seropositivity
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Quantitative titers of HCMV
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Seropositivity, log-transformed copies of HCMV, hcmv-miR-UL112
Number of subjects: 13
Study: 21690557

Group type: EXPERIMENTAL
Intervention: Pomalidomide 2 mg/d with dexamethasone 40 mg weekly
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Pomalidomide 4 mg/d with dexamethasone 40 mg weekly
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 70
Study: 21692673

Group type: EXPERIMENTAL
Intervention: Antiviral drug therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vaccination, antiviral strategies, and infection control measures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiviral therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunominimization
Number of subjects: 0
Study: 21692906

Group type: EXPERIMENTAL
Intervention: Subcutaneous immunoglobulin (SCIG) therapy
Number of subjects: 8
Study: 21692977

Group type: EXPERIMENTAL
Intervention: Clopidogrel treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Q192R genetic variant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paraoxonase-1 activity
Number of subjects: 0
Study: 21693250

Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS)
Number of subjects: 196
Study: 21693599

Group type: EXPERIMENTAL
Intervention: Subretinally implanted 16-electrode array
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Single-electrode activation
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Multiple-electrode activation
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Activation of compound patterns (simplified letters)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Concurrent retinal stimulation
Number of subjects: 11
Study: 21693614

Group type: EXPERIMENTAL
Intervention: Bayesian hierarchical model
Number of subjects: 257

Group type: COMPARATOR
Intervention: Ordinary least-squares (OLS) method
Number of subjects: 257
Study: 21694639

Group type: EXPERIMENTAL
Intervention: ADPKD-CHF patients
Number of subjects: 19
Study: 21696575

Group type: EXPERIMENTAL
Intervention: Vitamin D3-fortified yogurt drink (FYD; 500 IU vitamin D/250 mL)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Plain yogurt drink (PYD)
Number of subjects: 180
Study: 21696739

Group type: EXPERIMENTAL
Intervention: Mixed composition plaques by CCTA
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Primarily non-calcified plaques
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Primarily calcified plaques
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Non-calcified plaques
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Calcified plaques
Number of subjects: 230
Study: 21697252

Group type: EXPERIMENTAL
Intervention: Lanreotide acetate (Somatuline Autogel), 30 mg once a month, administered by deep subcutaneous injection.
Number of subjects: 2

Group type: COMPARATOR
Intervention: Octreotide via insulin pump (initial treatment).
Number of subjects: 2
Study: 21699130

Group type: EXPERIMENTAL
Intervention: Metronidazole gel 1%
Number of subjects: 30
Study: 21699369

Group type: EXPERIMENTAL
Intervention: 10 mg ezetimibe and 20 mg simvastatin once daily for 6 weeks
Number of subjects: 173
Study: 21699798

Group type: EXPERIMENTAL
Intervention: TG4040 vaccine (10⁶, 10⁷, or 10⁸ plaque-forming units) administered subcutaneously on days 1, 8, and 15.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: TG4040 vaccine (10⁸ plaque-forming units) administered subcutaneously.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: TG4040 vaccine (10⁸ plaque-forming units) with marked T-cell responses.
Number of subjects: 18
Study: 21699827

Group type: EXPERIMENTAL
Intervention: Lead complications causing reoperation after device implantation
Number of subjects: 28860

Group type: EXPERIMENTAL
Intervention: Right atrial (RA) lead complications
Number of subjects: 28860

Group type: EXPERIMENTAL
Intervention: Right ventricular lead complications
Number of subjects: 28860

Group type: EXPERIMENTAL
Intervention: Left ventricular lead complications
Number of subjects: 28860

Group type: EXPERIMENTAL
Intervention: Chronic heart failure as indication
Number of subjects: 28860

Group type: EXPERIMENTAL
Intervention: Implantation in a nonuniversity center
Number of subjects: 28860

Group type: EXPERIMENTAL
Intervention: Inexperienced operator with <25 implantations
Number of subjects: 28860

Group type: EXPERIMENTAL
Intervention: Single-lead RA device
Number of subjects: 28860

Group type: EXPERIMENTAL
Intervention: Dual-chamber pacing device
Number of subjects: 28860

Group type: EXPERIMENTAL
Intervention: CRT-P device
Number of subjects: 28860

Group type: EXPERIMENTAL
Intervention: Passive-fixation RA lead
Number of subjects: 28860
Study: 21699842

Group type: EXPERIMENTAL
Intervention: STV(Ratio)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: QTVI
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Combined criterion of highest quartile for both STV(Ratio) and QTVI
Number of subjects: 233
Study: 21700609

Group type: EXPERIMENTAL
Intervention: Transbronchial needle forceps (TBNF)
Number of subjects: 50
Study: 21700776

Group type: EXPERIMENTAL
Intervention: Decitabine (0.2 mg/kg subcutaneous 2 times per week for 12 weeks)
Number of subjects: 5
Study: 21701566

Group type: EXPERIMENTAL
Intervention: Lowest two quartiles of insulin sensitivity (S(I) <50th)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Most insulin sensitive (IS) individuals
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Most insulin resistant (IR) individuals
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Lowest quartile of S(I)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Highest two quartiles of insulin sensitivity (S(I) >50th)
Number of subjects: 122
Study: 21701807

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) measured on postoperative day 4 (POD 4)
Number of subjects: 1187

Group type: EXPERIMENTAL
Intervention: White blood cell counts (WBC)
Number of subjects: 1187

Group type: COMPARATOR
Intervention: Anastomotic leakage
Number of subjects: 1187

Group type: COMPARATOR
Intervention: Overall inflammatory complications
Number of subjects: 1187
Study: 21702914

Group type: EXPERIMENTAL
Intervention: Intensified taxane-based chemoradiotherapy (45 Gy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard neoadjuvant chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 18FDG-PET scans
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salvage docetaxel/cisplatin chemotherapy
Number of subjects: 0
Study: 21704134

Group type: EXPERIMENTAL
Intervention: Sleep deprivation (39 hours)
Number of subjects: 11
Study: 21704784

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 59
Study: 21704887

Group type: EXPERIMENTAL
Intervention: Bronchial thermoplasty (BT)
Number of subjects: 0
Study: 21704964

Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab monthly for 12 months
Number of subjects: 7
Study: 21705765

Group type: EXPERIMENTAL
Intervention: Essential newborn care practices
Number of subjects: 23356

Group type: EXPERIMENTAL
Intervention: Massage with mustard oil
Number of subjects: 23356

Group type: EXPERIMENTAL
Intervention: Sleeping in a warmed room
Number of subjects: 23356

Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact
Number of subjects: 23356
Study: 21705897

Group type: EXPERIMENTAL
Intervention: Chloride-rich fluids restriction (0.9% saline, Gelofusine, Albumex 4)
Number of subjects: 1644
Study: 21706288

Group type: EXPERIMENTAL
Intervention: Severe obstructive sleep apnea (OSA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (non-OSA)
Number of subjects: 60
Study: 21706316

Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Panobinostat
Number of subjects: 0
Study: 21707993

Group type: EXPERIMENTAL
Intervention: Physical activity > 400 kcal/day
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Increased fibrinogen
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Elevated resting heart rate
Number of subjects: 105

Group type: COMPARATOR
Intervention: MetS subjects
Number of subjects: 105

Group type: COMPARATOR
Intervention: PhA subjects
Number of subjects: 105
Study: 21708036

Group type: EXPERIMENTAL
Intervention: Cognitive performance assessment using neuropsychological battery tests, including the Mini-Mental State Examination and the 7 Minute Screen test.
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Screening tests applied during the study, such as the Mini-Mental State Examination and the 7 Minute Screen test.
Number of subjects: 420
Study: 21708874

Group type: EXPERIMENTAL
Intervention: Peak shear rate (SR(peak))
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Shear rate area under the curve through 30 seconds (SR(AUC 0-30))
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Shear rate area under the curve through 60 seconds (SR(AUC 0-60))
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Time to peak dilation (SR(AUC 0-ttp))
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Overall FMD response
Number of subjects: 50
Study: 21709058

Group type: EXPERIMENTAL
Intervention: 2-hour absolute (Δ) changes in high-sensitivity cTn T
Number of subjects: 836

Group type: COMPARATOR
Intervention: 2-hour relative (Δ%) changes in high-sensitivity cTn T
Number of subjects: 836

Group type: EXPERIMENTAL
Intervention: 2-hour absolute (Δ) changes in cTn I ultra
Number of subjects: 836

Group type: COMPARATOR
Intervention: 2-hour relative (Δ%) changes in cTn I ultra
Number of subjects: 836
Study: 21711530

Group type: EXPERIMENTAL
Intervention: Parental group support therapy, online/offline website, pediatrician involvement, video simulation game ('Dr. Cruz'), personalized biochemical feedback on exposure levels.
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Planned intervention in Stage II with 5-10 groups of 10 parents each.
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Cluster randomized controlled trial in Stage III.
Number of subjects: 540
Study: 21712287

Group type: EXPERIMENTAL
Intervention: HF-PEF
Number of subjects: 290

Group type: COMPARATOR
Intervention: HF-REF
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Both groups (HF-PEF and HF-REF)
Number of subjects: 290
Study: 21714604

Group type: EXPERIMENTAL
Intervention: Novel pharmacological and device-based approaches
Number of subjects: 0
Study: 21714878

Group type: COMPARATOR
Intervention: 800 mg/day ribavirin (group C) for 16 weeks
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: 400 mg/day ribavirin (group D) for 16 weeks
Number of subjects: 89

Group type: COMPARATOR
Intervention: 800 mg/day ribavirin (group C) for 16 weeks with low viral load
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: 400 mg/day ribavirin (group D) for 16 weeks with low viral load
Number of subjects: 89

Group type: COMPARATOR
Intervention: 800 mg/day ribavirin (group C) for 16 weeks with high viral load
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: 400 mg/day ribavirin (group D) for 16 weeks with high viral load
Number of subjects: 89
Study: 21715313

Group type: EXPERIMENTAL
Intervention: Reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin
Number of subjects: 83
Study: 21715509

Group type: EXPERIMENTAL
Intervention: 300 g yellow maize porridge containing 1.2 mg β-carotene, 20 g butter, and a 0.5-g corn oil capsule
Number of subjects: 8

Group type: COMPARATOR
Intervention: 1 mg [(13)C(10)]retinyl acetate in a 0.5-g corn oil capsule and 300 g white maize porridge with 20 g butter
Number of subjects: 8
Study: 21716163

Group type: EXPERIMENTAL
Intervention: HLA-DRB1 alleles (specifically DR4, DR11, DR14)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Intelligence and neuropsychological tests
Number of subjects: 141
Study: 21716260

Group type: EXPERIMENTAL
Intervention: 2 μg paricalcitol, orally active vitamin D receptor activator, every morning for 7 days
Number of subjects: 16
Study: 21716303

Group type: EXPERIMENTAL
Intervention: NV1FGF
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 21717386

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (5 or 10 mg) daily for 12 months
Number of subjects: 11
Study: 21719129

Group type: EXPERIMENTAL
Intervention: hsCRP levels ≥2mg/L
Number of subjects: 142

Group type: COMPARATOR
Intervention: hsCRP levels <2mg/L
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Higher hsCRP levels
Number of subjects: 142

Group type: COMPARATOR
Intervention: Lower hsCRP levels
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: hsCRP, LDL-cholesterol, BMI, and insulin resistance
Number of subjects: 142
Study: 21719124

Group type: EXPERIMENTAL
Intervention: Human Activity Profile (HAP)
Number of subjects: 101

Group type: COMPARATOR
Intervention: SF-36v2™ Physical Component Summary (PCS)
Number of subjects: 101
Study: 21719418

Group type: EXPERIMENTAL
Intervention: ACR70 responders
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: DAS-28 remission
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Moderate improvements
Number of subjects: 205
Study: 21719601

Group type: EXPERIMENTAL
Intervention: rVV-PR3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PR2-specific splenocytes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PR1-specific splenocytes
Number of subjects: 0
Study: 21719746

Group type: EXPERIMENTAL
Intervention: Obesity, gastroesophageal reflux, and smoking (combined risk factors)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: High body mass index (≥30)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Frequent acid reflux (≥1 time/week)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Frequent symptoms of acid reflux
Number of subjects: 364
Study: 21719884

Group type: EXPERIMENTAL
Intervention: Lenalidomide up to 30 mg daily for 16 weeks
Number of subjects: 28
Study: 21721925

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment, twice a week for 6 weeks
Number of subjects: 24
Study: 21723591

Group type: EXPERIMENTAL
Intervention: Hemoglobin levels below 14 g/dL
Number of subjects: 64850

Group type: EXPERIMENTAL
Intervention: NSAIDS use
Number of subjects: 64850

Group type: COMPARATOR
Intervention: Hemoglobin levels at or above 14 g/dL
Number of subjects: 64850
Study: 21724047

Group type: EXPERIMENTAL
Intervention: Nepafenac
Number of subjects: 0
Study: 21725047

Group type: EXPERIMENTAL
Intervention: Nonmyeloablative chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 0
Study: 21725050

Group type: EXPERIMENTAL
Intervention: Lenalidomide 5 mg daily for 56 days, then titrated up to 25 mg/d as tolerated
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lenalidomide therapy
Number of subjects: 60
Study: 21725056

Group type: EXPERIMENTAL
Intervention: Tipifarnib 300 mg twice daily on days 1-21 of each 28-day cycle
Number of subjects: 93